Tirzepatide

Overview

Tirzepatide is the active ingredient. Mounjaro is approved for type 2 diabetes; Zepbound for chronic weight management and obstructive sleep apnea in adults with obesity.

How It Works

It activates both GIP and GLP-1 receptors, affecting insulin release, appetite and digestion.

Approved Uses

Indications differ by product. Off-label use should be clearly distinguished from approved uses.

Clinical Evidence

The SURMOUNT and SURPASS trial programs studied weight and diabetes outcomes.

Common Side Effects

Nausea, diarrhea, decreased appetite, vomiting and constipation.

Important Warnings

Boxed warning regarding thyroid C-cell tumors. Discuss pancreatitis and gallbladder risks with your clinician.

Questions to Ask Your Healthcare Provider

• Is a GLP-1 medication appropriate for my health history?
• Which product and indication applies to me?
• What side effects should I watch for?
• How should I adjust nutrition and exercise?
• What happens if I stop the medication?

References

FDA product labeling and published trial reports. Full citations will be listed here.